抗血栓治疗背景下的鼻出血:因子Xa抑制剂与华法林及抗血小板药的比较
该回顾性队列研究比较了2011—2017年间因自发性鼻出血住院的成人患者,比较华法林、利伐沙班、阿哌沙班与抗血小板药组的出血特征、治疗与结局。共纳入109例,其中因子Xa抑制剂35例;多数为前部鼻出血(68%)。抗血小板组入院前鼻出血次数更多、需内镜手术止血更多;阿哌沙班组更常需烧灼联合填塞;因子Xa抑制剂组1年内因鼻出血再入院率较低;停用因子Xa抑制剂有效且无再出血。
要点
- 多数鼻出血为前部(68%),抗血小板组入院前出血次数更多且更常需内镜手术止血。
- 阿哌沙班组较利伐沙班和华法林组更常需烧灼联合填塞。
- 因子Xa抑制剂组1年内因鼻出血再入院率较低,停药有效且无再出血。
核心结论
- 因子Xa抑制剂相关鼻出血可有效治疗,结局不劣于甚至可能优于其他抗凝药。
研究设计与样本
- 回顾性队列研究,纳入2011—2017年因自发性鼻出血住院的成人患者共109例,其中因子Xa抑制剂35例,并设抗血小板药对照组。
- 华法林、利伐沙班、阿哌沙班和抗血小板组的平均随访期分别为18、14.5、13.5和18.2个月。
主要发现
- 多数患者表现为前部鼻出血(68%)。
- 抗血小板组入院前鼻出血发作次数多于抗凝药组(2.23 vs. 1.44,P < .05)。
- 抗血小板组需内镜手术控制出血的比例高于抗凝药组(23% vs. 6%,P < .05)。
- 阿哌沙班组需烧灼联合填塞的比例高于利伐沙班和华法林组(64% vs. 25%和33%,P < .05)。
- 随访1年内因鼻出血再入院率在因子Xa抑制剂组低于华法林和抗血小板组(16% vs. 9%和4%,P < .05)。
临床怎么用
- 对使用因子Xa抑制剂发生鼻出血的患者,可按常规鼻出血处理,必要时烧灼联合填塞。
- 停用因子Xa抑制剂对控制鼻出血有效且未观察到再出血事件。
局限性
- 证据等级为4级。
- 为回顾性队列研究,样本量有限(共109例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: To describe the characteristics and severity of epistaxis in patients taking factor Xa inhibitors novel anticoagulants. STUDY DESIGN: Retrospective cohort study. METHODS: A study of adult patients hospitalized due to spontaneous epistaxis under the treatment of warfarin, rivaroxaban, or apixaban between the years 2011 and 2017 was performed. A control group of patients under antiplatelet therapy (acetylsalicylic acid, clopidogrel) was included. The mean follow-up periods in the warfarin, rivaroxaban, apixaban, and antiplatelet groups were 18, 14.5, 13.5, and 18.2 months, respectively. We compared demographics, location and severity of bleeding, treatment methods, and outcome between the groups. RESULTS: The study included 109 patients (35 under factor Xa inhibitors), the majority of whom presented with anterior epistaxis (68%). The antiplatelet group had more episodes of epistaxis prior to admission, and required endoscopic surgical control of bleeding more often, in comparison with anticoagulants (2.23 vs. 1.44, P < .05 and 23% vs. 6%, respectively, P < .05). Among anticoagulants, combined therapy (cauterization and packing) was required more frequently in the apixaban group compared to the rivaroxaban and warfarin groups (64% vs. 25% and 33%, respectively, P < .05). The rate of readmissions due to epistaxis, within 1 year of follow-up was lower in the factor Xa inhibitor groups compared with the warfarin and antiplatelet groups (16% vs. 9% and 4%, respectively, P < .05). Cessation of factor Xa inhibitor therapy was effective and uneventful with no further epistaxis events. CONCLUSIONS: Epistaxis under factor Xa inhibitors was effectively treated with no worse and perhaps even a better outcome when compared to other anticlotting medications. LEVEL OF EVIDENCE: 4 Laryngoscope, 129:119-123, 2019.
引用
- Glikson E, Chavkin U, Madgar O, et al. Epistaxis in the setting of antithrombotic therapy: A comparison between factor Xa inhibitors, warfarin, and antiplatelet agents. Laryngoscope. 2018. PMID: 30325496. doi:10.1002/lary.27400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。